Regeneron Expands Canadian Presence with New Headquarters for Better Patient Care

Regeneron, a leading biotechnology company, has announced the opening of its first headquarters in Mississauga, Ontario, as part of its ongoing commitment to better serve the needs of Canadian patients with serious diseases. The new facility, located in the thriving biotechnology hub of Mississauga, is a significant step in the company's long-term global growth strategy.

The opening of Regeneron's new headquarters in Mississauga aligns with the company's strategic goals in several ways. Firstly, the region is known for its highly-skilled workforce and thriving research environment, which is crucial for Regeneron's operations and the advancement of the next frontier of medicine in Canada. Secondly, Canada is a large and growing market for biotechnology and life sciences, and establishing a presence in Mississauga allows Regeneron to better serve Canadian patients and potentially expand its customer base. Lastly, the company's investment in Mississauga contributes to Ontario's position as a global leader in biomanufacturing, fostering innovation, and driving the development of next-generation health solutions.

Regeneron's expansion into Mississauga is also supported by local and provincial government officials, indicating a positive business climate for the company's growth and expansion. Nina Tangri, Associate Minister of Small Business and MPP Mississauga – Streetsville, Deepak Anand, MPP for Mississauga – Malton, Brett McDermott, Director of Government and Stakeholder Relations, Mississauga Board of Trade, and Bradley Harker, Principal Commercial Officer, U.S. Commercial Service | U.S. Department of Commerce | International Trade Administration, US Embassy and Consulates in Canada, all attended the opening ceremony.

Regeneron's investment in Canada, particularly in the biotechnology sector, contributes significantly to the growth and development of the Canadian economy, as well as the local community and the broader healthcare industry. The company's presence in Mississauga is expected to create jobs and stimulate economic growth in the region. Additionally, Regeneron's commitment to R&D in the biotechnology sector fosters innovation and drives the development of next-generation health solutions, contributing to Canada's reputation as a global leader in biomanufacturing.

The company's portfolio includes numerous approved treatments and product candidates for various therapeutic areas, such as eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. By bringing these medicines to Canada, Regeneron contributes to the growth and development of the broader healthcare industry, improving patient outcomes and quality of life.

In conclusion, Regeneron's expansion into Canada, particularly with the opening of its first headquarters in Mississauga, aligns with the company's long-term global growth strategy. The new facility contributes to the growth and development of the Canadian economy, the local community, and the broader healthcare industry. With its commitment to R&D, innovation, and patient care, Regeneron is well-positioned to continue its success in the Canadian market.